Skip to main content
. 2022 Jul 6;13:911225. doi: 10.3389/fendo.2022.911225

Table 2.

Controlled ovarian stimulation cycle related characteristics of the training and validation cohorts.

Training cohort Validation cohort Training vs. validation
Controln = 11,918 Moderate/severe OHSS n = 293 Totaln = 12211 P value Controln = 5102 Moderate/severe OHSS n = 132 Totaln = 5234 P value P value
COS cycle number 1 (1–1) 1 (1–1) 0.003 1 (1–1) 1 (1–1) 1 (1–1) 0.027 0.339
 First cycle 9,621 (80.73%) 260 (88.74%) 9,881 (80.92%) 4,085 (80.07%) 117 (88.64%) 4,202 (80.28%)
 Second cycle 2,052 (17.22%) 32 (10.92%) 2,084 (17.07%) 910 (17.84%) 14 (10.61%) 924 (17.65%)
COS protocol 0.605
 GnRH agonist protocol 7,399 (62.1%) 185 (63.1%) 7,584 (62.1%) 0.712 3,148 (61.7%) 81 (61.4%) 3,229 (61.7%) 0.937 0.605
 GnRH antagonist protocol 4,519 (37.9%) 108 (36.9%) 4,627 (37.9%) 1,954 (38.3%) 51 (38.6%) 2,005 (38.3%)
Gn duration 11.15 ± 2.22 10.79 ± 1.94 11.14 ± 2.22 0.012 11.11 ± 2.23 11.09 ± 2.27 11.11 ± 2.24 0.952 0.145
Total dose of Gn (IU) 2,025 (1,500–2,775) 1650 (1,231.25–2,175) 2025 (1,500–2,737.5) <.001 2,025 (1,500–2,812.5) 1637 (1,200–2,090.63) 2,025 (1,500–2,775) <.001 0.466
Mean dose of Gn (IU) 187.5 (150–225) 150 (125–187.5) 187.5 (150–225) <.001 187.5 (150–230) 150 (125–187.5) 187.5 (150–230) <.001 0.062
Initial dose of Gn (IU) 150 (150–225) 150 (112.5–150) 150 (150–225) <.001 150 (150–225) 150 (112.5–150) 150 (150–225) <.001 0.025
Number of follicles on trigger day
 Follicles ≥ 10 mm 17 (11–24) 19 (14–26) 17 (11–24) <.001 17 (11–24) 20 (15–32) 17 (11–24) <.001 0.543
 Follicles ≥ 14 mm 10 (7–13) 11 (9–14) 10 (7–13) <.001 10 (7–13) 12 (9–16.5) 10 (7–13) <.001 0.828
 Follicles ≥ 16 mm 7 (5–9) 8 (6–10) 7 (5–9) <.001 7 (5–9) 7.5 (6–10) 7 (5–9) 0.002 0.669
 Follicles ≥ 18 mm 4 (2–5) 4 (3–6) 4 (2–5) 0.002 4 (2–5) 4 (2–5) 4 (2–5) 0.299 0.644
Hormonal levels on trigger day
 LH (IU/L) 1.33 ± 1.45 1.45 ± 1.42 1.33 ± 1.45 0.037 1.31 ± 1.15 1.25 ± 1.05 1.31 ± 1.15 0.29 0.445
 P (nmol/L) 2.77 ± 1.98 2.43 ± 1.42 2.76 ± 1.97 <.001 2.79 ± 1.77 2.80 ± 2.07 2.79 ± 1.77 0.319 0.271
 E2 (pmol/L) 0.038 0.006 0.796
  E2 ≤ 1,835 69 (0.6%) 0 (0.0%) 69 (0.6%) 25 (0.5%) 0 (0.0%) 25 (0.5%)
  1,835 < E2 ≤ 3,670 408 (3.4%) 2 (0.7%) 410 (3.4%) 165 (3.2%) 0 (0.0%) 165 (3.2%)
  3,670 < E2 ≤ 18,350 8,895 (74.6%) 225 (76.8%) 9,120 (74.7%) 3,833 (75.1%) 90 (68.2%) 3,923 (75.0%)
  E2 > 18,350 2,546 (21.4%) 66 (22.5%) 2,612 (21.4%) 1,079 (21.1%) 42 (31.8%) 1,121 (21.4%)
Type of trigger
 HCG alone 10,135 (85.0%) 284 (96.9%) 10,419 (85.3%) <.001 4,313 (84.5%) 123 (93.2%) 4,436 (84.8%) 0.013 0.556
 GnRHa alone 644 (5.4%) 1 (0.3%) 645 (5.3%) 294 (5.8%) 1 (0.8%) 295 (5.6%)
 Dual trigger 1,139 (9.6%) 8 (2.7%) 1,147 (9.4%) 495 (9.7%) 8 (6.1%) 503 (9.6%)
Number of oocytes retrieved 13 (9–18) 15.5 (11–22) 13 (9–18) <.001 13 (9–18) 15.5 (11–22) 13 (9–18) <.001 0.779
 ≤10 4,218 (35.4%) 73 (24.9%) 4,291 (35.1%) <.001 1,844 (36.1%) 30 (22.7%) 1,874 (35.8%) <.001 0.594
 11–20 5,637 (47.3%) 175 (59.7%) 5,812 (47.6%) 2,378 (46.6%) 61 (46.2%) 2,439 (46.6%)
 21–30 1,719 (14.4%) 32 (10.9%) 1,751 (14.3%) 727 (14.2%) 29 (22.0%) 756 (14.4%)
 > 30 344 (2.9%) 13 (4.4%) 357 (2.9%) 153 (3.0%) 12 (9.1%) 165 (3.2%)
Freeze all
 No 7,469 (62.7%) 232 (79.2%) 7,701 (63.1%) <.001 3,172 (62.2%) 89 (67.4%) 3,261 (62.3%) 0.219 0.340
 Yes 4,449 (37.3%) 61 (20.8%) 4,510 (36.9%) 1,930 (37.8%) 43 (32.6%) 1,973 (37.7%)
Fertilization type
 1 = IVF 9,786 (82.1%) 246 (84.0%) 10,032 (82.2%) 0.623 4,145 (81.2%) 108 (81.8%) 4,253 (81.3%) 0.951 0.178
 2 = ICSI 2,118 (17.8%) 47 (16.0%) 2,165 (17.7%) 954 (18.7%) 24 (18.2%) 978 (18.7%)
 3 = IVF/ICSI 14 (0.1%) 0 (0.0%) 14 (0.1%) 3 (0.1%) 0 (0.0%) 3 (0.1%)
Origin of sperm
 1 = husband 11,852 (99.4%) 290 (99.0%) 12,142 (99.4%) 0.289 5,071 (99.4%) 131 (99.2%) 5,202 (99.4%) 0.827 0.712
 2 = sperm bank 66 (0.6%) 3 (1.0%) 69 (0.6%) 31 (0.6%) 1 (0.8%) 32 (0.6%)
Type of sperm
 1 = fresh 11,799 (99.0%) 289 (98.6%) 12,088 (99.0%) 0.535 5,050 (99.0%) 131 (99.2%) 5,181 (99.0%) 0.767 0.974
 2 = frozen 119 (1.0%) 4 (1.4%) 123 (1.0%) 52 (1.0%) 1 (0.8%) 53 (1.0%) 0.349
Number of cycles with ET 6,078 (51.0%) 216 (73.7%) 6,294 (51.5%) <.001 2,574 (50.5%) 82 (62.1%) 2,656 (50.7%) 0.008 0.334
Number of cycles with canceled ET 5,840 (49.0%) 77 (26.3%) 5,917 (48.5%) 2,528 (49.5%) 50 (37.9%) 2,578 (49.3%)
Number of embryos for ET 2 (1,2) 2 (2,2) 2 (1,2) 0.026 2 (1,2) 2 (2,2) 2 (1,2) 0.122 0.233
n = 1 1,902 (31.3%) 50 (23.1%) 1,952 (31.0%) 0.025 842 (32.7%) 19 (22.6%) 861 (32.4%) 0.059 0.399
n = 2 4,082 (67.2%) 164 (75.9%) 4,246 (67.5%) 1,689 (65.6%) 65 (77.4%) 1,754 (66.0%)
n = 3 94 (1.5%) 2 (0.9%) 96 (1.5%) 43 (1.7%) 0 (0.0%) 43 (1.6%)
Number of top-quality embryos for ET 1 (0,2) 1 (1,2) 1 (0,2) <.001 1 (0,2) 2 (1,2) 1 (0,2) 0.001 0.506
n = 0 1,885 (31.0%) 45 (20.8%) 1,930 (30.7%) <.001 747 (29.0%) 15 (18.3%) 762 (28.7%) 0.004 0.089
n = 1 2,161 (35.6%) 72 (33.0%) 2,233 (35.5%) 987 (38.3%) 25 (30.5%) 1,012 (38.1%)
n = 2 2,006 (33.0%) 98 (45.4%) 2,104 (33.4%) 831 (32.3%) 42 (51.2%) 873 (32.9%)
Number of blastocysts for ET 0 (0,0) 0 (0,0) 0 (0,0) 0.566 0 (0,0) 0 (0,0) 0 (0,0) 0.753 0.662
n = 0 5,265 (86.6%) 184 (85.2%) 5,449 (86.6%) 0.076 2,237 (86.9%) 72 (87.8%) 2,309 (86.9%) 0.341 0.778
n = 1 674 (11.1%) 31 (14.4%) 705 (11.2%) 275 (10.7%) 10 (12.2%) 285 (10.7%)
n = 2 139 (2.3%) 1 (0.5%) 140 (2.2%) 62 (2.4%) 0 (0.0%) 62 (2.3%)

OHSS, ovarian hyper-stimulation syndrome; COS, controlled ovarian stimulation; GnRH, gonadotropin-releasing hormone; Gn, gonadotropin; LH, luteinizing hormone; P, progesterone; E2, estradiol; HCG, human chorionic gonadotropin; GnRHa, gonadotropin-releasing hormone agonist; IVF, in vitro fertilization; ICSI, intra-cytoplasmic sperm injection; ET, embryo transfer.